argenx NV ADR (ARGX)vsCreative Medical Technology Holdings Inc (CELZ)
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
CELZ
Creative Medical Technology Holdings Inc
$0.70
-3.40%
HEALTHCARE · Cap: $5.49M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 197182200% more annual revenue ($5.92B vs $3,000). ARGX leads profitability with a 31.7% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CELZ
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Intrinsic value data unavailable for CELZ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 358.9% YoY
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
0.0% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : CELZ
The strongest argument for CELZ centers on Price/Book, EPS Growth.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CELZ
The primary concerns for CELZ are Revenue Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CELZ is a value play — different risk/reward profiles.
CELZ carries more volatility with a beta of 1.91 — expect wider price swings.
ARGX is growing revenue faster at 52.1% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 33/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Creative Medical Technology Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company is headquartered in Phoenix, Arizona.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?